Looking ahead to potentially curative therapies, CRISPR/Cas is a revolutionary genome editing technology8–11 that if successfully developed to correct CFTR mutations could be a transformative advance resulting in long-lasting therapies for all Cystic Fibrosis (CF) patients, including those with nonsense mutations. The gene discussed is CFTR; the disease is cystic fibrosis.